DEF: VSee Health Faces Going Concern Warning, Seeks Shareholder Votes

VSee Health, Inc. will hold its Annual Meeting on December 15, 2025, to vote on director elections, auditor ratification, and a new equity incentive plan, amidst disclosures of financial difficulties and deferred executive salaries.

Summary

• The Annual Meeting of Stockholders for VSee Health, Inc. will be held virtually on December 15, 2025, at 2:30 P.M. Eastern Time.
• Stockholders will vote on four proposals: electing two Class I directors, ratifying WWC, P.C. as the independent auditor for fiscal year 2025, approving the VSee Health, Inc. 2025 Equity Incentive Plan, and approving the adjournment of the meeting if necessary.
• The Board of Directors unanimously recommends voting FOR all nominees and proposals.
• As of the Record Date (November 20, 2025), there were 32,289,750 shares of Common Stock and 1,788 shares of Preferred Stock outstanding, totaling 32,468,550 votes.
• A quorum requires shares representing a majority of voting power, specifically 16,148,104 Common Stock votes and 89,418 Preferred Stock votes.
• The 2025 Equity Incentive Plan proposes to authorize 2,553,403 shares of Common Stock for issuance, with an evergreen formula to increase shares annually by 15% of outstanding shares.
• The company's cybersecurity measures are in a developmental stage, lacking formalized protocols, a dedicated team, or comprehensive risk assessments.
• Executive officers' salaries for 2024 and 2023 were deferred, with the company stating that timely payments would "further jeopardize our ability to continue as a going concern."
• Audit fees for the year ended December 31, 2024, were approximately $1,870,422, a significant increase from $15,040 in 2023.
• Several related party transactions involved the conversion of loans and working capital advances into common stock, including a $2,000,000 secured convertible promissory note issued to an affiliate of a major investor in December 2024.
• Two late Form 4 filings for Mr. Sands and one late Form 4 filing for Dr. Aisiku were noted for Section 16(a) reports during 2024.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the explicit disclosure of 'going concern' issues, deferred executive salaries, and a 'troubled debt restructuring.' These are critical indicators of severe financial distress, overshadowing standard governance proposals and future growth plans. The lack of formalized cybersecurity measures further compounds the negative outlook.

Positives

• The Board of Directors unanimously recommends all proposals, indicating internal alignment on governance and incentive structures.
• The company has established a comprehensive corporate governance framework, including Audit, Compensation, and Nominating and Corporate Governance Committees, a Code of Business Conduct and Ethics, an Insider Trading Policy, and a Clawback Policy.
• The Board actively oversees various risks, including credit, liquidity, cybersecurity, and operational risks, with specific committees assigned oversight responsibilities.
• The proposed 2025 Equity Incentive Plan aims to attract, retain, and motivate key personnel, which is crucial for long-term strategic growth.

Negatives

• Executive officers' salaries for 2024 and 2023 were deferred because timely payments would "further jeopardize our ability to continue as a going concern," indicating severe financial distress.
• The company engaged in a "troubled debt restructuring" in November 2024, converting $405,000 of working capital advances from a related party into common stock, signaling financial difficulties.
• Cybersecurity measures are in a developmental stage, with no formalized framework, dedicated team, or specific protocols, leaving the company vulnerable to cyberattacks and data breaches.
• Audit fees increased dramatically from $15,040 in 2023 to $1,870,422 in 2024, which could suggest increased complexity or issues in financial reporting.
• Two late Form 4 filings for Mr. Sands and one late Form 4 filing for Dr. Aisiku indicate lapses in compliance with Section 16(a) reporting requirements.

Risks

• The company's developmental stage cybersecurity posture leaves it vulnerable to cyberattacks, data breaches, unauthorized access to sensitive information, business disruptions, regulatory fines, litigation costs, and negative reputational impact.
• The explicit statement regarding the company's ability to continue as a going concern due to deferred executive salaries highlights significant solvency and operational risks.
• The evolving landscape of cybersecurity risks means that even with future improvements, there is no assurance that initiatives will fully mitigate threats.
• Potential for excise tax under Section 280G and Section 4999 of the Code on certain compensation payments in a change of control event.
• Limitations on the deductibility of compensation under Section 162(m) of the Code could impact the company's tax efficiency.

Future Outlook

The company is actively evaluating its cybersecurity needs and developing appropriate measures to enhance its cybersecurity posture, including considering external experts and incident response strategies. The goal is to establish a cybersecurity framework commensurate with its size and operations. The company also intends to make deferred salary payments to executive officers as soon as it is financially able. The proposed 2025 Equity Incentive Plan is designed to attract, retain, and motivate key contributors for the company's long-term strategic growth.

Management Comments

• Our Board of Directors believes that each of the Director Proposal, the Auditor Proposal, the Incentive Plan Proposal, and the Adjournment Proposal is in the best interests of our Company and our stockholders and unanimously recommends that its stockholders vote FOR each of the nominees for the Director Proposal and FOR each of the other Proposals to be presented at the Annual Meeting.
• Our Board believes that Dr. Chen's years of management experience in our industry as well as his extensive understanding of our business, operations and strategy make him well qualified to serve as Chairman of our board of directors.
• Our Board of Directors believes that the adoption of the 2025 Plan is necessary and in the best interests of the Company and its long-term strategic growth to permit us to continue to attract, retain and motivate our employees, consultants and directors.
• The Company determined that the partial settlement of the working capital advances represented a troubled debt restructuring, as the Company determined it was experiencing financial difficulties and the lender granted a concession through the exchange for shares of Common Stock.
• Executive officers' salaries were deferred because timely payments further jeopardize our ability to continue as a going concern. We intend to make such payments as soon as we are able.

Industry Context

This filing provides insight into the corporate governance and financial health of a company operating in the digital health and telehealth sector. The emphasis on attracting and retaining talent through equity incentive plans is a common strategy in technology-driven industries. However, the disclosed financial difficulties and lack of formalized cybersecurity measures are significant concerns, especially in the healthcare industry where data privacy and security are paramount and regulatory scrutiny is high. The substantial increase in audit fees could also reflect the complexities of operating in a highly regulated and evolving market.

Comparison to Industry Standards

• The company's admission that timely payment of executive salaries would "further jeopardize our ability to continue as a going concern" is a severe deviation from the financial stability expected of publicly traded companies, particularly in the established digital health sector.
• The lack of formalized cybersecurity measures, a dedicated team, or specific protocols is significantly below industry standards for a public company handling sensitive health data, especially when compared to leading telehealth providers like Teladoc Health or Amwell, which invest heavily in robust security frameworks.
• The engagement in a "troubled debt restructuring" and conversion of working capital advances into equity indicates a level of financial distress that is not typical for healthy, growing companies in the digital health space.
• The dramatic increase in audit fees from $15,040 in 2023 to $1,870,422 in 2024 is an outlier and suggests potential underlying financial complexities, restatements, or significant audit challenges that are not usually seen in stable companies.
• While equity incentive plans are standard for talent retention, the context of deferred executive salaries and going concern warnings makes the effectiveness and perception of the 2025 Equity Incentive Plan questionable compared to industry peers offering competitive compensation packages.

Management Changes

Corporate Governance

Legal Proceedings

• Our directors and executive officers were not involved in any legal proceedings as described in Item 401(f) of Regulation S-K in the past ten years.
• Two late Form 4 filings for Mr. Sands and one late Form 4 filing for Dr. Aisiku were noted for Section 16(a) reporting requirements during the year ended December 31, 2024.

Related Party Transactions

• On October 4, 2023, DHAC issued an unsecured promissory note of $165,000 to M2B, an affiliate of Digital Health Sponsor, LLC (the sponsor of DHAC), which was paid off on January 31, 2024.
• On November 21, 2023, loans incurred by VSee Lab to the Bridge Investor (an investor in the Sponsor) in the aggregate amount of $600,000 were converted into the Company's common stock.
• On November 21, 2023, loans incurred by iDoc to Tidewater Ventures, LLC (an affiliate of the Sponsor) in the aggregate amount of $585,000 were converted into the Company's common stock.
• On November 21, 2023, loans incurred by iDoc to the Bridge Investor in the aggregate amount of $600,000 were converted into the Company's common stock.
• On December 31, 2024, the Company entered into the Ascent Purchase Agreement with Ascent (an affiliate of the Bridge Investor) for a $2,000,000 secured convertible promissory note at 10.00% interest, convertible into common stock at $2.00 per share.
• On November 8, 2024, SCS, LLC (an affiliate of the Sponsor) converted $405,000 of working capital advances into 202,500 shares of Common Stock, which the Company determined was a "troubled debt restructuring." Approximately $52,000 of working capital advances from the Sponsor and affiliates remain due.
• DHAC entered into a registration rights agreement on October 5, 2022 (amended January 22, 2024) with the Bridge Investor for shares underlying Bridge Warrants, bridge commitment shares, and Bridge Notes.
• Pursuant to amended and restated Conversion SPAs on February 13, 2024, DHAC agreed to provide registration rights to the Bridge Investor and Tidewater for shares upon conversion of certain assumed notes.
• The Company entered into a registration rights agreement with the Quantum Investor on July 9, 2024, for shares underlying the Quantum Note.
• The Company and Ascent entered into a registration rights agreement on September 30, 2024, for shares underlying the Ascent Note and Ascent Warrants.
• On October 5, 2022, DHAC, VSee, and iDoc issued $2,222,222 in 10% original issue discount senior secured promissory notes (Bridge Notes) to the Bridge Investor, along with 173,913 warrants and 30,000 shares of DHAC common stock.
• On June 21, 2024, the Company entered into a Consulting Services Agreement with SCS, LLC (an affiliate of the Sponsor) for $12,500 per month for business consulting services.
• On November 21, 2023, DHAC, VSee, and iDoc entered into a letter agreement with the Bridge Investor to purchase additional 10% original issue discount senior secured convertible promissory notes (Additional Bridge Notes) totaling $166,667 (subscription $150,000), bearing 8.00% interest and convertible into DHAC common stock at $10 per share.
• On March 28, 2024, iDoc issued a secured convertible promissory note of $224,000 to Mr. David L. Wickersham (a member of the Board of Directors), which was satisfied by the issuance of 114,000 shares of the Company's common stock.

Stakeholder Impact

• Shareholders: Will vote on critical governance matters (directors, auditor, equity plan) and face potential dilution from the proposed 2025 Equity Incentive Plan and past related-party conversions. The "going concern" warning and troubled debt restructuring indicate significant risk to share value.
• Employees: Eligible to participate in the new equity incentive plan, but the company's financial difficulties and deferred executive salaries raise concerns about overall compensation stability and job security.
• Customers: Potential reputational damage from financial instability and unaddressed cybersecurity vulnerabilities could erode trust, especially in a healthcare context.
• Creditors: Those involved in the troubled debt restructuring have already converted debt to equity, and remaining creditors face heightened risk due to the company's "going concern" issues.
• Management: Have had salaries deferred, indicating direct financial impact, and are responsible for navigating the company through its financial challenges and improving its cybersecurity posture.

Next Steps

• Hold the Annual Meeting of Stockholders on December 15, 2025, to vote on the proposed resolutions.
• Elect two Class I directors to serve until the 2028 annual meeting.
• Ratify the appointment of WWC, P.C. as the independent registered public accounting firm for fiscal year 2025.
• Approve the VSee Health, Inc. 2025 Equity Incentive Plan.
• Continue evaluating cybersecurity needs and developing appropriate measures to enhance cybersecurity posture.
• Assess and update cybersecurity measures in response to emerging threats.
• Make deferred salary payments to executive officers as soon as the company is financially able.

Key Dates

Recommendation

The filing contains explicit and severe indicators of financial distress, including the company's statement that timely payment of executive salaries would "further jeopardize our ability to continue as a going concern." This is a critical red flag for solvency. The recent "troubled debt restructuring" and significant increase in audit fees from 2023 to 2024 further underscore deep-seated financial difficulties. While the annual meeting addresses standard governance matters, the underlying financial health disclosures suggest a high probability of continued operational challenges and potential for significant share price depreciation. A seasoned investor would view these disclosures as a strong signal to exit the position.

Keywords

Proxy Statement, Annual Meeting, Corporate Governance, Equity Incentive Plan, Financial Distress, Going Concern, Related Party Transactions, Cybersecurity Risk, Executive Compensation, Auditor Ratification, VSee Health